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Abstract
Combretastatin A4 phosphate (CA4P) causes rapid
disruption of the tumor vasculature and is currently
being evaluated for antivascular therapy. We describe
the initial results obtained with a noninvasive multi-
parametric magnetic resonance imaging (MRI) ap-
proach to assess the early effects of CA4P on rat
bladder tumors implanted on nude mice. MRI (4.7 T)
comprised a fast spin-echo sequence for growth curve
assessment; a multislice multiecho sequence for
T2 measurement before, 15 minutes after, and 24 hours
after CA4P (100 mg/kg); and a fast T2w* gradient-echo
sequence to assess MR signal modification under
carbogen breathing before, 35 minutes after, and
24 hours after CA4P. The tumor fraction with increased
T2w* signal intensity under carbogen (T
+) was used to
quantify CA4P effect on functional vasculature. CA4P
slowed tumor growth over 24 hours and accelerated
necrosis development. T + decrease was observed
already at 35 minutes post-CA4P. Early T2 increase
was observed in regions becoming necrotic at 24 hours
post-CA4P, as confirmed by high T2 and histology.
These regions exhibited, under carbogen, a switch from
T2w* signal increase before CA4P to a decrease post-
CA4P. The combination of carbogen-based functional
MRI and T2 measurement may be useful for the early
follow-up of antivascular therapy without the admin-
istration of contrast agents.
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Introduction
Combretastatin A4 phosphate (CA4P) is a member of a
class of low-molecular-weight vascular-disrupting agents
(VDAs) that are currently in preclinical and clinical develop-
ment for antivascular tumor therapy [1,2]. This tubulin-
binding drug causes rapid collapse in tumor blood flow in vivo,
most likely due to disruption of the tubulin cytoskeleton, leading
to morphologic changes in endothelial cells. Effects occur
rapidly at concentrations well below the maximum tolerated
dose and are largely specific to the tumor vasculature. This
specificity is currently under investigation, but there is evidence
that it correlates with increased vascular permeability—a prop-
erty of new tumor vessels [3]. A further increase of permeability
by CA4P exposure would therefore lead to massive protein
leakage, edema, increase in interstitial fluid pressure, and, fi-
nally, vascular collapse [1].
The drug has been evaluated on various experimental
tumors in rats and mice, with varying results, most likely de-
pending on tumor types and CA4P scheduling and doses. It is
currently in phase II clinical trial, and new variants of the drug
are under development [4]. From these studies and trials, it
turned out that the drug needs to be used in combination with
other drugs. It seems to be, indeed, much less efficient on the
peripheral tumor vasculature, leaving a viable rim from which
the tumor can start growing again.
In this situation (i.e., rapid and heterogeneous response), a
precise combination therapy scheduling, which will ideally
require noninvasive therapy follow-up by imaging methods
with high spatial resolution for safe and frequent measure-
ments, is expected to be mandatory. This holds for preclinical
studies on tumor models that are used for the development of
combination therapies, as well as for clinical trials and, eventu-
ally, clinical routine.
Noninvasive magnetic resonance imaging (MRI) and mag-
netic resonance spectroscopy (MRS) techniques may become
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important tools in the performance of this follow-up. Several
experimental studies using MRI or MRS techniques have
already shown that administration of CA4P can affect
a number of MRI/MRS measurable parameters such as
transfer constant K trans and initial area under the curve
(IAUC), which are provided by dynamic contrast-enhanced
(DCE)MRI, apparent water diffusion coefficient (ADC), tumor
blood volume, and Pi/NTP [3,5–11].
More precisely, recent studies byDCE-MRI in animals and
humans revealed reduction of K trans or IAUC hours after
CA4P administration, which is indicative of a rapid decrease
of tumor perfusion [5,7,9–11].
Very recently, Thoeny et al. observed, after CA4P treat-
ment, an early decrease of the ADC, followed by an ADC
increase, and again a decrease. These findings were attrib-
uted to initially nonperfused but viable tumor tissues, appear-
ance of necrosis, and subsequent tumor regrowth [6].
We recently used carbogen-based functional MRI (fMRI)
for longitudinal follow-up of a chemically induced hepato-
cellular carcinoma in mice, and we suggested a new
parameter T + (the fraction of tumor voxels with increased T2*-
weighted intensity under carbogen) for noninvasive assess-
ment of therapies involving vasculature-targeting drugs [12].
In the current paper, we demonstrate that T + is, indeed,
modified very early after CA4P administration in a highly vas-
cularized rat bladder tumor model implanted on nude mice.
Carbogen-based fMRI was combined with anatomic high-
resolution MRI and T2 measurements leading to a multi-
parametric MRI protocol for therapy follow-up.
Materials and Methods
Tumor Model
Tumors were grown from NSF14 cells, which are NBTII
carcinoma cells stably transfected with fibroblast growth
factor-1 (FGF-1 or acidic FGF). NBTII cells were derived
from a chemically induced rat bladder carcinoma. These cells
do not produce endogenous FGF-1 but possess the FGFR-
2b high-affinity FGF-1 receptor on their surface. NSF14 cells
are therefore autocrine for this growth factor and are highly
tumorigenic after subcutaneous injection into nude mice
[13]. The tumors are highly vascularized as a result of
FGF-1 production, release of this potent angiogenic growth
factor, and paracrine activation of host endothelial cells
[14,15]. Consequently, these tumors are expected to be par-
ticularly sensitive to CA4P treatment.
NSF14 cells were routinely cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum,
2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin (complete medium); no further growth in selective
medium was needed. FGF-1 expression and production were
maintained over the passages and in vivo; the recent use
of these autocrine cells was reported by Billottet et al. [15].
Tumors were obtained on the flank after subcutaneous
inoculation of 5  106 cells/animal. They developed rapidly,
and animals were sacrificed within 2 to 3 weeks. Experiments
were carried out 6 to 9 days postinduction.
Experiments were performed in accordance with the
guidelines for animal experimentation from the Ministe`re de
l’Agriculture et de la Peˆche (authorization no. 91-123).
CA4P
CA4 was synthesized following the method reported by
Lawrence et al. [16] then converted, as previously described,
into its disodium phosphate prodrug, CA4P [17]. Before each
experiment, CA4Pwas dissolved in sterile saline (0.9%NaCl)
and given intraperitoneally as single injection at a dose of
100 mg/kg body weight.
MRI
Seven mice were treated with CA4P, and six mice served
as controls to determine tumor growth and necrosis without
treatment. For MRI experiments, mice were anesthetized
with isoflurane (4% for induction; 1.5–2% for maintenance
during the entire experiment) and placed in a home-built
cradle in supine position. Tubes containing circulating warm
water were placed close to the animal to maintain a constant
body temperature at 35.7jC (± 0.9jC).
MRI was performed with a 4.7-T Bruker Biospec 47/30
system (BRUKER BioSpin GmbH, Ettlingen, Germany)
equipped with actively shielded gradients (200 mT/m) using
a homemade slotted cylinder-type radiofrequency probe
(d = 44 mm). Respiratory triggering was performed using a
highly sensitive home-built pneumatic system, as described
previously [18].
The imaging protocol comprised three sequences:
1. A fast spin-echo sequence (‘‘3D RARE’’) was used for
high-resolution screening of the whole tumor and for
the measurement of growth curves [field of view
(FOV) = 3  3  2.5 cm3; matrix dimension = 256 
256  50; RARE factor = 16; and weighted echo time
TEw = 41 milliseconds]. Repetition time (TR) was
determined by actual respiratory frequency, which
could be slightly modulated by anesthesia gas con-
centration, and was kept at around 2 seconds. The
acquisition window (2.8 milliseconds) was centered
with respect to respiratory motion peaks by means of
an adjustable trigger delay (integrated in the external
trigger device). This ensured optimal image quality.
Tumor volume was measured by manual delineation
of tumor borders on each slice of the high-resolution
3D RARE image block.
2. A multislice multiecho (MSME) sequence was used for
quantitative T2 measurements to characterize CA4P
effects on this parameter (FOV = 3 cm2; matrix
dimension = 128  128; slice thickness = 1 mm; TRc
2 seconds; TE min = 9.6 milliseconds; and equidistant
echoes = 8). Parametric T2 images were calculated by
monoexponential fitting (ParaVision; BRUKERBioSpin
GmbH). As necrosis was characterized by long T2 re-
laxation times in this model, it was determined on T2
maps by counting the pixels above a T2 threshold of
93 milliseconds. This threshold was fixed once on an
arbitrarily selected T2 slice containing necrotic regions
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in such a manner that the MRI-estimated necrotic
fractionmatched that determined on the corresponding
histologic section (vide infra). The percentage of tumor
necrosis was then estimated from all slices covering
the whole tumor.
3. fMRI was prepared by the optimization of B0 homoge-
neity over the tumor using localized shimming (x, y, z)
with a one-shot stimulated echo localization sequence
(volume-selective stimulated echo protocol; volume
dimensions of about 1 cm3). fMRI was then performed
using a fast gradient-echo (GRE) imaging sequence
(‘‘GEFI’’ protocol; FOV = 3 cm2; slice thickness = 1mm;
TE = 16.3 milliseconds; TR = 26.6 milliseconds; and flip
angle a = 30j), as described in more detail previously
[19]. Briefly, 80 sets of 15 slices covering the whole
tumor were acquired during the following protocol of
breathing gas administration: image sets 1 to 7:
reconstituted air (20% O2/80% N2); image sets 8 to
10: transition delay air–carbogen; image sets 11 to
48: carbogen (95% O2/5% CO2); image sets 49 to 51:
transition delay carbogen–air; image sets 52 to 80:
reconstituted air. Breathing gas was delivered at 2 l/min
through a nosepiece.
fMRI data were processed according to two different pro-
tocols: 1) the time course of relative T2w* signal intensity (SI)
variation I/I0 in response to carbogen breathing was re-
corded in regions of interest (ROI) defined on T2 maps;
2) images were treated, pixel by pixel, using homemade
programs under IDL (Research Systems, Inc., Boulder, CO):
difference images were calculated by subtracting mean
images (n = 7) from the mean image corresponding to the first
set. Only significantly different values (Student’s t test,PV .05)
were retained for the difference images. They allowed vi-
sualization of the spatial distribution of carbogen response.
Furthermore, they were used to measure the tumor fractions
exhibiting positive [i.e., signal increase (fraction T+)], negative
[i.e., signal decrease (fraction T)], or no significant re-
sponse [(fraction T 0)] to carbogen breathing [12]. These frac-
tions were determined by counting corresponding pixels for all
slices covering the whole tumor. ROI for T +, T, and T 0 mea-
surements delimited the whole tumor on each slice. For that,
tumor ROI, animal contour, and some anatomic landmarks
(spinal cord and vessels) were first carefully defined on high-
resolution/high-contrast images from the MSME sequence
set. The whole contour pattern was then positioned on the
corresponding GRE mean image with the help of anatomic
landmarks. Indeed, due to the lower resolution and the lower
contrast of the GRE images, this was considered as the most
objective procedure of tumor ROI positioning.
fMR images were acquired before, about 35 minutes after,
and 24 hours after CA4P injection. Intraperitoneal injection
after the control measurement was performed outside the
magnetwithoutmoving theanesthetizedmouse from its cradle.
To perform the 35-minute measurement, the cradle was then
reinserted into the magnet at the very same position as before.
In addition to tumor measurements, the response to
carbogen breathing was systematically monitored in a region
comprising the inferior vena cava and the portal vein to verify
carbogen arrival into the blood. Indeed, in the presence of
carbogen, a signal increase in this region was systematically
observed, as described previously [12,19].
Histopathology
Tumors were excised for histopathology directly after the
last MRI experiment (i.e., 24 hours after CA4P administration
for the treated group). After sacrifice (cervical dislocation),
tumors were removed and embedded in OCT (Tissue-Tek,
Sakura, Japan), frozen, and serially cut at 20jC in 4-mm-
thick slices. Sections were stained with hematoxylin and
stained immunochemically for assessment of necrosis, and
for qualitative and quantitative descriptions of microvascula-
ture-related characteristics, as described hereafter. Vessels
were highlighted by staining the endothelial cells immuno-
chemically for factor VIII (vonWillebrand factor) [20]. Staining
was carried out using the Dako EnVision kit K4010 (Dako,
Trappes, France), with the following protocol: 4-mm-thick
sections were fixed in acetone at 4jC (10 minutes). Sections
were incubated with peroxidase block for 5 minutes to
quench any endogenous peroxidase activity. After washing
carefully (5 minutes) with phosphate-buffered saline (PBS)
solution, the sections were incubated (30 minutes) with a
diluted (1:400) rabbit anti–human von Willebrand factor
(polyclonal antibody, code no. A-0082; Dako), which recog-
nizes an endothelial cell surface marker factor VIII, at room
temperature. After washing with PBS for 5 minutes, the sec-
tions were incubated with peroxidase polymer for 30 min-
utes. After washing in a PBS solution (5 minutes), the
sections were stained by a 10-minute incubation with 3,3V-
diaminobenzidine tetrahydrochloride substrate chromogen,
which resulted in a brown precipitate at the antigen site
(20 ml/ml). Hematoxylin was used for counterstaining. Differ-
ent incubation steps then dehydrated the sections: 95% al-
cohol (10 minutes), 100% alcohol (10 minutes, thrice),
toluene–alcohol (50/50) mixture (10 minutes), and 100%
toluene (10 minutes, twice). Finally, sections were mounted
with a cover glass using Eukitt (EMS, Hatfield, PA).
For estimation of tumor necrosis, six adjacent sections
located at the tumor center at 200-mm intervals were selected
and scanned at 4000 dpi (Nikon Super Coolscan 8000,
Tokyo, Japan). The percentage of necrosis was determined
by manual delimitation using Amira software (Mercury Com-
puter Systems; TGS, Bordeaux, France).
Apparent microvessel density (MVD) was estimated on
immunochemically stained sections in two different rectan-
gular regions, areas 1 and 2 (1.5 1.1mm), characterized by
different T2 evolutions observed on colocalized MRI slices
after CA4P administration. MVD estimation was carried out
without knowledge of the areas’ category. Individual micro-
vessels were counted on digitized images acquired on a
Zeiss Axiophot microscope (Carl Zeiss AG, Oberkochen,
Germany) equipped with a DXC-990P camera (Sony, Tokyo,
Japan) at a final magnification of 140. Using CAD software
(CorelDRAW; Corel Corporation, Ottawa, Canada), a grid
was superimposed on the section to facilitate counting.
An apparent microvessel was defined as any stained
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endothelial cell or cell cluster separated from an adjacent
one. Five tumors were inspected.
Statistical Analysis
Correlation of necrotic fractions determined by histology
and on T2 maps was assessed by linear regression analysis
(P < .05 was considered statistically significant). A com-
parison of necrotic fractions, tumor growth, MVD values,
T + values, I/I0 values, and T2 values was performed using
the Mann-Whitney U test (P < .05 was considered statisti-
cally significant).
Results
Anatomic MRI and Histology
Control tumors without any treatment were characterized
by rapid growth. The mean tumor growth rate was 122 ±
68% per day. Treatment by CA4P considerably slowed
growth for all tumors (n = 5; two mice died before the second
tumor volume determination). The growth rate was 15 ± 24%
per day and was statistically different from that of the
control group.
Hematoxylin-stained sections revealed that necrosis frac-
tion was significantly higher in the CA4P-treated group (34 ±
18%) than in the control group (12 ± 15%). Furthermore,
evolution of necrosis fraction over 24 hours could be studied
in both groups through noninvasive estimation by MRI.
Indeed, necrotic regions were detected as high T2 regions
in tumors (Figure 1C), and necrotic fractions determined by
histology (Figure 1A) and on T2 maps were highly correlated
[(necHis) = 0.79(necT2) + 13.1; r = 0.99, P = .003].
For all treated tumors, we observed a significant increase
of necrosis 24 hours after CA4P administration. The necrotic
fraction was 25 ± 13% before CA4P administration and was
41 ± 17% afterward. For comparison, in the control group,
the percentage of necrosis was 13 ± 9% on the first day and
was 18 ± 12% after 24 hours (nonsignificant).
fMRI and Histology
Signal modification on carbogen breathing was observed
with the fMRI protocol on all untreated tumors (i.e., control
group and treated group pre-CA4P; n = 13). However, spa-
tial distribution of carbogen response was heterogeneous,
with different time course patterns observed in the same
tumor (Figure 2).
CA4P treatment drastically modified carbogen response
in the tumors. Typical examples are given in Figures 2 and 3.
Figure 2 represents carbogen response in three areas of
the same tumor, revealing different response evolutions
after CA4P administration: positive response during the car-
bogen breathing time slot before CA4P treatment and slightly
negative response 35 minutes after treatment (Figure 2A);
no response to carbogen, neither before nor after CA4P
treatment (Figure 2B); and continuous signal increase on
carbogen before CA4P treatment and continuous signal de-
crease after CA4P treatment (Figure 2C). Interestingly, the
latter region corresponded to necrosis, as detected on the
Figure 1. Comparison of a histologic section (anti – factor VIII staining; scale
bar = 1 mm) of a tumor treated by CA4P (A), with corresponding T2 maps
before (B) and 24 hours after CA4P administration (C) (black dots on the
post-CA4P T2 map correspond to pixels with fit failure).
Figure 2. Time courses of T2w* signal modification I/I0 during carbogen
breathing before (filled symbols) and 35 minutes after (open symbols) CA4P
administration. In a given tumor, three regions could be distinguished by the
different effects of CA4P on response to carbogen breathing. (A) Initial T2w*
signal increase on carbogen disappeared post-CA4P. (B) No response to
carbogen neither before nor after CA4P treatment. (C) Initial continuous
signal increase switched to continuous signal decrease post-CA4P.
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corresponding T2 map and histologic section (regions are
depicted in Figure 6A).
Typical images of carbogen response before CA4P treat-
ment and its evolution after treatment are shown on Figure 3.
For three tumors, the difference images corresponding to a
slice passing through the tumor center and taken in the
middle of the carbogen time slot are depicted. The most ap-
parent effect of CA4P treatment seemed to be a decrease
of positively responding regions in favor of negatively re-
sponding or nonresponding regions (Figure 3, G, H, and I ).
Tumor vessel damage caused by CA4P administration
was visible on histologic sections. Indeed, immunochemical
staining of the vasculature yielded a rather anarchic pattern,
which was compatible with important vessel disorganization
and vasculature disruption in nonnecrotic areas (Figure 4).
Evolution of the overall response to carbogen was
assessed in all treated tumors by measuring fractions with
positive (T +), negative (T), and no (T 0) response (cf. Ma-
terials and Methods section). This procedure was referred
to as ‘‘functional tumor segmentation.’’
The pre-CA4P and post-CA4P time courses of these
fractions averaged over all tumors are depicted in Figure 5.
They showed, at 35 minutes and 24 hours post-CA4P, an
important decrease of mean T+ (Figure 5A), as well as an
increase of mean T 0 and T (Figure 5, B andC), with a slight
nonsignificant trend of recovery toward pre-CA4P values at
24 hours post-CA4P. The highest decrease of mean T + was
observed between 24 and 36 minutes after carbogen onset
[T +(35 minutes post-CA4P) / T +(before) = 0.43]. Within this
time slot, T +(35minutes post-CA4P) was always significantly
different from T +(before); for T 0, the corresponding differ-
ence was only significant at the 30-minute measurement;
and for T, the corresponding difference was not significant.
T + was therefore considered as the most sensitive param-
eter evaluating CA4P effect.
As already stated above, T2 maps were used to estimate
tumor necrosis before and 24 hours after CA4P adminis-
tration. A detailed examination of T2 maps revealed that
T2 relaxation was already modified in some tumor regions
at about 15minutes post-CA4P.More precisely, after analysis
of one axial slice passing through the tumor center, different
areas could be distinguished in terms ofT2 variation (Figure 6,
A and B): area 1, where T2 decreased 15 minutes after CA4P
administration and recovered 24 hours after CA4P ad-
ministration; area 2, where T2 did not change after CA4P ad-
ministration; and area 3, where T2 continually increased after
Figure 3. Visualization of CA4P effect on functional difference images of three tumors (rows). Each row shows a high-resolution T2-weighted image of a slice
passing through the tumor center (A–C) and the corresponding T2w* difference images taken at the center of the carbogen time slot before (D–F) and 35 minutes
after (G– I) CA4P administration. The background gray value corresponds to no significant response under carbogen breathing; higher and lower gray values
correspond, respectively, to significant positive and negative responses (apparent response outside the animal is due to residual respiratory motion artifacts). After
CA4P administration, the disappearance of positively responding regions and the appearance of negatively responding or nonresponding regions are visible in
these examples. Scale bar = 1 cm.
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CA4P administration. Furthermore, after examination of the
different corresponding areas on histologic sections stained
with factor VIII (Figure 6A), we observed, for all tumors, that
area 1 had higher apparent MVD (651 vessels/mm2 ± 102)
than area 2 (296 vessels/mm2 ± 40, P = .001), and that
area 3 corresponded to necrotic and ‘‘prenecrotic’’ regions.
Qualitatively, compared to area 2, in area 1, the vessel lumen
was more visible and the network architecture seemed to be
more anarchic with more vessel ramifications.
In addition, I/I0 ratios weremeasured in these areas during
the central time slot shown in Figure 5. The results are
depicted in Figure 6C. In area 1, I/I0 decreased significantly
at 35 minutes after CA4P administration, but no further
significant decrease at 24 hours was observed. In area 2,
I/I0 was not modified by CA4P; in area 3, the necrotic area
was characterized by an important decrease of I/I0 at
35 minutes after CA4P, which was even more pronounced
at 24 hours.
Discussion
In the present study, the early effect of the administration
of a unique CA4P dose to nude mice bearing subcuta-
neously grown hypervascular rat bladder tumors was as-
sessed by completely noninvasive MRI approaches and by
histology. The effects of CA4Pon tumor growth, necrosis, and
functional vasculature were demonstrated by comparing a
nontreated control group with the treated group, and, more
importantly, by performing a 24-hour longitudinal follow-up
of CA4P administration on the treated group.
Tumor Growth and Morphology
We observed that rat bladder’s tumor growth rate was
considerably slowed by a unique dose of CA4P at 100mg/kg.
Our results are in accordance with those of Ahmed et al. [21],
which were obtained on R1 rat rhabdomyosarcoma, but
differed from those of Chaplin and Hill [22], who observed
nonsignificant growth retardation on murine tumors (CaNT).
The discrepancy with respect to the latter study might be
explained by the tumor model used in our study, which should
contain a high fraction of permeable neovessels due to an
overproduction of FGF-1. This property is likely to sensitize
the tumor to VDAs [1].
The longitudinal follow-up of necrosis on T2 maps con-
firmed the tumor structure modification and destruction in-
duced by CA4P in our model. Indeed, we observed a 62%
increase of necrosis fraction at 24 hours posttreatment, com-
pared to a 41% increase over 24 hours in the control group.
Furthermore, modifications of vascular aspects, namely,
important vessel disorganization and vasculature disruption,
were observed in nonnecrotic areas on factor VIII–stained
histologic sections.
Functional Vasculature
The effect of CA4P on functional tumor vasculature was
evaluated by carbogen-based fMRI, using our recently intro-
duced approach for functional segmentation, wherewe quan-
tify tumor fractions with positive, negative, or no response
after about 30 minutes of carbogen breathing.
From the results depicted in Figure 5, we concluded that
T + should be the most sensitive parameter to follow CA4P
effect. In our experiments, the first post-CA4P fMRI mea-
surement was performed about half an hour after drug
administration. This was the earliest possible time point
compatible with our experimental MRI protocol. At this mo-
ment, a significant T + decrease was observed, which is
compatible with an acute decrease in tumor perfusion con-
sequent to vascular destruction. Indeed, other groups, using
various methods [positron emission tomography (PET),
DCE-MRI, and autoradiography], also described a very early
decrease in tumor perfusion in various human and experi-
mental tumors following CA4P administration [10,23–25].
Tozer et al. [26], using intravital microscopy, showed that a
complete tumor blood flow shutdown can be obtained within
20 minutes after VDA administration. Zhao et al. [27] found a
significant decrease in perfusion/permeability at 2 hours fol-
lowing CA4P administration. In addition, in a recent phase I
clinical trial, Anderson et al. [23] showed significant reduc-
tions in tumor perfusion, as measured with PET 30 minutes
after CA4P administration. A very rapid response was de-
scribed by Hori et al. [28] using the hydrogen clearance
method with a CA4P derivative (AC7700). They observed,
using intravital microscopy, that tumor blood flow began to
decrease immediately after drug administration and reached
a minimum at approximately 30 minutes after injection. All
Figure 4. Histologic sections stained with hematoxylin and antibody anti –
factor VIII (slice thickness = 4 m) of (A; left) a control tumor and (A; right) a
treated tumor (scale bar = 1 mm). (B) Comparison of the rectangular regions
at higher magnification (20) reveals vessel damage caused by CA4P
administration in the treated tumor. Arrows indicate distinct vessels with
lumen on the control tumor section, which are hardly visible on the treated
tumor section.
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these observations are, indeed, consistent with known phar-
macokinetic data of CA4P. CA4P is rapidly dephosphorylated
by nonspecific endogenous phosphatases that are present
in plasma and on endothelial cells to the active CA4 with a
half-life of a few minutes [8].
In our study, the mean T + measured at 24 hours was
similar to the value at 35 minutes post-CA4P, indicating the
persistence of CA4P effect on the tumor vasculature for this
tumor model, which may also provide an explanation for a
nearly arrested tumor growth. However, an apparent trend
of reincrease of T + at 24 hours may indicate the start of a
progressive recovery of the functional vasculature that is
prone to triggering tumor regrowth, as described by others [5].
Interestingly, an early effect of CA4P was not only ob-
served on carbogen-based fMRI but also on parametric T2
maps without carbogen breathing. In fact, in all tumors, we
identified regions characterized, at 15minutes post-CA4P, by
either T2 decrease (area 1), unchanged T2 (area 2), or T2 in-
crease (area 3). We will discuss this observation in more
detail (Figure 6). I/I0 modification under carbogen measured
in the same regions revealed a switch from signal increase
to no modification, no modification before and after CA4P,
Figure 5. Evolution of (A) mean T + fractions, (B) mean T 0 fractions, and (C) mean T fractions during carbogen breathing before (black rhombi), about 35 minutes
after (open rhombi), and 24 hours after (gray rhombi) CA4P administration (asterisks indicate statistical differences). Dotted boxes indicate the time window for
T2w* signal measurements during longitudinal follow-up (cf. Figures 3 and 6).
Effects of CA4P on Tumor Growth and Vascularization Thomas et al. 593
Neoplasia . Vol. 8, No. 7, 2006
and from signal increase to signal decrease. The behavior of
the latter region, obviously the most sensitive to CA4P, might
be explained by rapid edema formation [1] (higher T2) and a
‘‘steal effect’’ [19,29] during carbogen breathing (T2w* SI de-
crease). CA4P treatment should indeed create such tumor
regions with definitely nonfunctional vasculature, which may
generate or enhance such a steal effect. This region was ne-
crotic at 24 hours (histology) and was characterized by even
higher T2, and, more importantly, T2w* SI decrease.
CA4P administration had apparently no effect on MRI pa-
rameters measured in area 2. MVD estimation on factor
VIII–stained histologic sections provided a much lower value
in this region (about 300 vessels/mm2) compared to area 1
(about 650 vessels/mm2). From the current study, we cannot
decide whether functional MVD in this region was too low
to produce a carbogen effect, or, on the contrary, whether the
region was well oxygenated through a mature and robust
vasculature, which would also be less sensitive to CA4P.
The earlyT2 decrease (area 1)might be due to an increase
of deoxyhemoglobin as a consequence of vascular disrup-
tion, which should be also responsible for the disappearance
of carbogen response in this region at 35minutes post-CA4P.
However, with this hypothesis, damage would be less se-
vere than in area 3, as T2 recovered at 24 hours and the re-
gion was not necrotic.
These results also demonstrate the spatial heterogeneity
of CA4P effect in our tumor model. Some authors who used
the contrast-enhancing agent GdDTPAonmouse and human
tumors models also observed an important response hetero-
geneity to CA4P [3]. They hypothesized, based on the study
of Furman-Haran et al. [30], that this heterogeneity may be
explained by the angiogenic ‘‘hot spots’’ that exist around
necrotic regions of tumors and indicate a heterogeneous
distribution of growth factors. For this group, the vascular
disruption caused by CA4P results more in the loss of per-
fusion in specific tumor regions, rather than in the reduction
of the overall rate of perfusion in the tumor. However, Maxwell
et al. [10], assessing the CA4P antivascular effect by DCE-
MRI in rats bearing P22 carcinosarcomas, did not observe
any significant tumor heterogeneity.
Further studies, including histology at 35 minutes post-
CA4P or DCE-MRI, will be necessary to better understand
vascular and cellular modifications that produce the early ef-
fects on T2 and T2w* SI.
In conclusion, the present experimental work at 4.7 T
demonstrated, for the first time, that completely noninvasive
fMRI based on carbogen breathing provides a new param-
eter (the tumor fraction T +) that is useful for monitoring the
early effects of antivascular drugs in tumors. Modifications
of T2w* SI under carbogen were detected in some tumor re-
gions at about half an hour after CA4P administration. In
addition, our results suggest that a CA4P effect can be de-
tected early even by classic T2 mapping without carbogen
breathing, and a combination of both parameters may better
assess the sensitivity of the tumor to CA4P treatment. The
predictive value of the observed early modifications for
therapy outcome will have to be further studied. Carbogen-
based fMRI, alone or in combination with T2 mapping, may
become a tool for noninvasive follow-up of therapies involv-
ing VDAs, using MRI sequences routinely available on clini-
cal systems and avoiding the administration of exogenous
contrast agents.
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